Announced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus: Strong Market Position and Growth Potential Justify Buy Rating
- Analysts Spot 3 Strong Buy Russell 2000 Stocks with 100% Upside
- Positive Outlook for Lantheus: Strategic Adjustments and Steady Price Target Support Buy Rating
- Lantheus Completes Acquisition of Life Molecular Imaging
- Lantheus completes acquisition of Life Molecular Imaging